SHANGHAI - China will refine its centralised drug procurement policy, an official report said on Wednesday, after a recent probe into quality concerns, of off-patent medicines approved for distribution to public hospitals.
"We will refine the policy for centralised medicine procurement and enhance quality evaluations and oversight to ensure that our people have full confidence in the medication they use," said the report.
The report added that China would also "improve pricing mechanisms", and create a "medical insurance catalogue" for innovative drugs to "support their development".
China's healthcare regulator in February said that the quality concerns were unsubstantiated.
&uuid=(email))